AURA Aura Biosciences, Inc.
Price Chart
Executive Summary
Aura Biosciences reported Q4 and full-year 2025 financial results, highlighting accelerated enrollment in its Phase 3 CoMpass trial for early choroidal melanoma with topline data expected in 2H 2027. The company has $144.2 million in cash, sufficient to fund operations into Q1 2027. Net loss increased to $106.2 million in 2025 from $86.9 million in 2024, primarily due to higher R&D expenses.
Key Financial Metrics
Actionable Insight
The clinical progress in the CoMpass trial is a positive development, but the widening net loss raises concerns about sustainability. Investors should monitor the mid-2026 enrollment completion and mid-2026 NMIBC data readouts as key catalysts. The extended cash runway reduces near-term dilution risk.
Key Facts
- Completed enrollment in Phase 3 CoMpass trial now expected by mid-2026, with topline data anticipated in second half of 2027
- Initial 3-month clinical data from Phase 1b/2 NMIBC trial expected mid-2026
- New formulation of bel-sar achieved 12-month stability, expanding potential in non-ocular solid tumors
- Cash and marketable securities totaled $144.2 million as of December 31, 2025
- R&D expenses increased to $90.3 million in 2025 from $73.3 million in 2024
- Net loss widened to $106.2 million in 2025 from $86.9 million in 2024
- Cash runway extends into Q1 2027
Financial Impact
Net loss increased by $19.3 million year-over-year, driven by higher R&D spending. Cash position grew to $144.2 million despite increased burn.
Risk Factors
- Clinical trial timelines could slip despite current enrollment momentum
- Increased R&D spend may pressure cash runway if fundraising is delayed
- No efficacy data yet reported; future results may not meet expectations
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264473 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 19, 2026
24d ago
|
Press Release
| $7.47 $7.50 | ▲ +0.40% | ▼ −1.40% | $6.41 (−14.19%) |
|
May 5, 2026
5w ago
|
8-K
| $8.29 $7.93 | ▲ +4.34% | ▲ +5.47% | $6.41 (+22.68%) |
|
May 5, 2026
5w ago
|
Press Release
| $8.29 $7.93 | ▲ +4.34% | ▲ +5.47% | $6.41 (+22.68%) |
|
May 4, 2026
5w ago
|
8-K
| $8.90 $7.93 | ▼ −10.90% | ▼ −12.88% | $6.41 (−27.98%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.35 $8.19 | ▲ +1.92% | ▲ +4.85% | $6.41 (+23.23%) |
|
May 4, 2026
5w ago
|
424B5
| $8.35 $8.19 | ▲ +1.92% | ▲ +4.85% | $6.41 (+23.23%) |
|
May 4, 2026
5w ago
|
8-K
| $8.35 $8.19 | ▼ −1.92% | ▼ −4.85% | $6.41 (−23.23%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.35 $8.19 | ▲ +1.92% | ▲ +4.85% | $6.41 (+23.23%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.35 $8.19 | ▼ −1.92% | ▼ −4.85% | $6.41 (−23.23%) |
|
Apr 20, 2026
7w ago
|
DEFA14A
| $7.44 $6.96 | ▼ −6.45% | ▼ −7.54% | $6.41 (−13.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access